Pharma channel feed

Eli Lil­ly adds new board mem­ber Kim­ber­ly John­son, the COO who helped lead Fan­nie Mae out of the US hous­ing cri­sis

5 years ago
People

Weeks af­ter drop­ping big re­sponse da­ta, Am­gen lines up pri­or­i­ty re­view for KRAS hope­ful so­tora­sib in NSCLC

5 years ago
FDA+

No­var­tis' En­tresto, fac­ing a big come­back in hard-to-treat heart fail­ure pa­tients, scores FDA nod af­ter ad­comm cake­walk

5 years ago
FDA+

In a rare le­gal de­feat, Bris­tol My­ers Squibb and Sanofi fined $834M for 'de­cep­tive mar­ket­ing' on best-sell­ing blood thin­ner Plav­ix

5 years ago

An­oth­er Keytru­da com­bo tops stan­dard of care in ad­vanced kid­ney can­cer, pos­ing new test for Bris­tol's I/O med

5 years ago

Astel­las, Seagen pave the way for Pad­cev's glob­al roll­out with full con­fir­ma­to­ry da­ta for urothe­lial can­cer in hand

5 years ago
FDA+

Am­gen los­es ap­peal in patent suit against Sanofi/Re­gen­eron’s Pralu­ent. It’s a bum­mer for Bris­tol My­ers Squibb and Mer­ck, too

5 years ago

Eli Lil­ly ousts CFO Josh Smi­ley af­ter 'i­nap­pro­pri­ate re­la­tion­ship' with em­ploy­ee, ap­points suc­ces­sor in Anat Ashke­nazi

5 years ago
People

For­mer Gale­na chief Mark Ahn back in hot wa­ter as DOJ lev­els in­sid­er trad­ing charges for con­sul­tant work

5 years ago
People

Bris­tol My­ers Squibb earns long-await­ed FDA nod for liso-cel, join­ing short list of lym­phoma CAR-T win­ners

5 years ago
FDA+

FDA blasts Mer­ck­'s bid for ad­ju­vant Keytru­da in TNBC be­fore ad­comm, call­ing late-stage da­ta 'ques­tion­able'

5 years ago
FDA+

Re­gen­eron has a win­ner in Dupix­ent and big sales hopes. So why are so few pa­tients tak­ing it?

5 years ago

Sanofi flunks Parkin­son's Phase II, ax­es hand­ful of mid-stage pro­grams in Q4 earn­ings

5 years ago

Shift to dig­i­tal leaves hun­dreds of Am­gen sales jobs on chop­ping block

5 years ago

Mer­ck KGaA goes toe to toe with No­var­tis as FDA green-lights MET in­hibitor

5 years ago
FDA+

Year-end earn­ings show tur­bu­lent times for Hal Bar­ron's Glax­o­SmithK­line turn­around

5 years ago

Neu­ro­crine ax­es Parkin­son's col­lab with Voy­ager af­ter safe­ty is­sues, jeop­ar­diz­ing biotech's long-run­ning cen­ter­piece

5 years ago

#WCLC21: Mer­ck pokes Bris­tol My­ers in the eye with Keytru­da da­ta show­ing safe­ty red flags in Yer­voy com­bo tri­al

5 years ago

#WCLC21: As­traZeneca's EGFR in­hibitor Tagris­so cuts re­lapse, death risks in pa­tients with and with­out pri­or chemother­a­py

5 years ago

J&J her­alds 66% ef­fi­ca­cy for sin­gle-dose shot, but falls short of mR­NA ri­vals

5 years ago
Coronavirus

Drug­mak­ers 'inch­ing ahead' in in­creas­ing ac­cess to drugs world­wide, with Glax­o­SmithK­line lead­ing the pack

5 years ago

Lon­za look­ing to build on 'd­if­fer­en­ti­at­ed ad­van­tage' in Covid-19, CD­MO mar­ket­place in 2021

5 years ago
Manufacturing

BIO looks to re­struc­ture, lay­ing off staff amid chal­lenge to the trade org's nor­mal face-to-face style

5 years ago

Bio­Med Re­al­ty snaps up in­no­va­tion cam­pus site with­in earshot of pricey and bustling Boston biotech hub

5 years ago
First page Previous page 246247248249250251252 Next page Last page
A service from the Financial Times